Tweet
Clin Vaccine Immunol. 2012 Jan 18. [Epub ahead of print]
Immunogenicity Persistence of a Monovalent Influenza A/H1N1 2009 Vaccine in Healthy Volunteers.
Lai YC, Yang KC, Hsieh SM, Yao CA, Lee LT, Huang KC.
Source
Department of Family Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Abstract
After WHO declared H1N1 pandemic, global vaccination was carried immediately after several researches. However, the data of long-term immunogenicity was lacking. We aimed to investigate the long-term immunogenicity of different H1N1 vaccine dosage groups 24 weeks after the vaccination by a randomized clinical trial. A total of 218 participants were stratified into adult (≤60 years) and elderly (>60 years) groups. The adults were randomized in a 1:1:1 ratio. First group received single dose of vaccine with 15 mcg hemagglutination antigen (HA). The other two groups received two doses with 15 mcg or 30 mcg HA triweekly. The elderly were randomized 1:1 for two doses of 15 or 30 mcg HA. We evaluated serologic responses at pre-vaccination, week 3, 6 and 24. We also examined possible associated factors of immunogenicity by multivariate logistic regression analyses. At week 24, seroprotection (Anti-HA antibody level ≥ 1:40) remained in 76.8% and 46.2% in the adult and elderly groups. The adult group had higher seroprotection rate (odds ratio of 2.98, 95% CI: 1.21-7.36) than elderly. There was no statistical difference of seroprotection and seroconversion rates among different dosage groups in adult or elderly. Lower immunogenicity was observed in the elders than the adults 24 weeks after the vaccination. However, there was no statistical significant difference among different dose groups. Therefore, we suggested that only single dose of 15 mcg HA vaccination for the adults and two doses of 15mcg HA for the elderly in the future.
PMID:
22258708
[PubMed - as supplied by publisher]
Immunogenicity Persistence of a Monovalent Influenza A/H1N1 2009 Vaccine in Healthy Volunteers.
Lai YC, Yang KC, Hsieh SM, Yao CA, Lee LT, Huang KC.
Source
Department of Family Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Abstract
After WHO declared H1N1 pandemic, global vaccination was carried immediately after several researches. However, the data of long-term immunogenicity was lacking. We aimed to investigate the long-term immunogenicity of different H1N1 vaccine dosage groups 24 weeks after the vaccination by a randomized clinical trial. A total of 218 participants were stratified into adult (≤60 years) and elderly (>60 years) groups. The adults were randomized in a 1:1:1 ratio. First group received single dose of vaccine with 15 mcg hemagglutination antigen (HA). The other two groups received two doses with 15 mcg or 30 mcg HA triweekly. The elderly were randomized 1:1 for two doses of 15 or 30 mcg HA. We evaluated serologic responses at pre-vaccination, week 3, 6 and 24. We also examined possible associated factors of immunogenicity by multivariate logistic regression analyses. At week 24, seroprotection (Anti-HA antibody level ≥ 1:40) remained in 76.8% and 46.2% in the adult and elderly groups. The adult group had higher seroprotection rate (odds ratio of 2.98, 95% CI: 1.21-7.36) than elderly. There was no statistical difference of seroprotection and seroconversion rates among different dosage groups in adult or elderly. Lower immunogenicity was observed in the elders than the adults 24 weeks after the vaccination. However, there was no statistical significant difference among different dose groups. Therefore, we suggested that only single dose of 15 mcg HA vaccination for the adults and two doses of 15mcg HA for the elderly in the future.
PMID:
22258708
[PubMed - as supplied by publisher]
